Explore Pfizer’s evolving pipeline strategy, expanding into oncology and obesity to drive growth beyond its COVID-19 success.
The US Food and Drug Administration (FDA) has granted full approval to pharma giant Pfizer’s Braftovi (encorafenib) in combination with cetuximab (marketed as Erbitux) and fluorouracil-based ...
Pfizer Inc. has acquired exclusive rights to commercialize an obesity therapy in China, strengthening its push into the ...
In a decisive move finalized on Thursday, Pfizer secured a pivotal agreement with Beam Therapeutics. The deal grants Pfizer exclusive global rights to a novel gene-editing program targeting the liver.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results